Jiangsu Nhwa Pharmaceutical Co., LTD (SHE:002262)

SHE:002262 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	2,082	1,416	2,159	1,532	1,608	1,402
Trading Asset Securities	1,912	2,373	1,335	1,452	1,058	837
Cash & Short-Term Investments	3,994	3,789	3,494	2,984	2,666	2,239
Cash Growth	8.94%	8.46%	17.08%	11.94%	19.05%	13.06%
Accounts Receivable	1,718	1,496	1,054	843.93	720.49	609.22
Other Receivables	55.43	49.07	41.84	42.52	27.61	19.35
Receivables	1,774	1,545	1,095	886.45	748.09	628.57
Inventory	665.41	661.39	628.64	716.34	604.33	433.86
Prepaid Expenses	-	5.45	0	0	4.81	-
Other Current Assets	65.34	57.84	36.63	63.4	19.96	17.73
Total Current Assets	6,498	6,060	5,255	4,650	4,043	3,320
Property, Plant & Equipment	1,572	1,609	1,496	1,304	1,158	1,034
Long-Term Investments	126.94	125.31	106.77	118.61	130.41	81.23
Other Intangible Assets	227.52	232.09	190.47	111.1	95.98	101.04
Long-Term Deferred Tax Assets	57.91	55.39	58.32	36.95	30.66	31.2
Long-Term Deferred Charges	268.48	263.61	128.03	131.88	80.51	25.95
Other Long-Term Assets	117.22	95.2	94.05	128.51	158.09	155.18
Total Assets	8,869	8,440	7,328	6,481	5,697	4,748
Accounts Payable	614.6	568.35	277.2	255.74	267.17	165.19
Accrued Expenses	-	180.54	296.13	297.36	53.09	38.73
Short-Term Debt	10	15	55	30	38	38
Current Portion of Leases	21.49	20.18	20.86	20.63	25.01	-
Current Income Taxes Payable	191.48	91.28	84.1	83.5	80.85	97.91
Current Unearned Revenue	26.27	41.53	26.49	26.7	24.11	41.07
Other Current Liabilities	317.67	149.37	54.26	80.02	193.72	194.05
Total Current Liabilities	1,182	1,066	814.03	793.94	681.96	574.95
Long-Term Debt	0.23	0.23	0.23	0.23	0.23	0.23
Long-Term Leases	28.5	33.87	35.56	41.91	47.67	-
Long-Term Unearned Revenue	41.41	41.41	53.87	58.05	63.6	67.77
Long-Term Deferred Tax Liabilities	-	0.11	1.46	3.3	-	-
Other Long-Term Liabilities	24.64	24.64	12.95	-	-	-
Total Liabilities	1,276	1,166	918.09	897.43	793.45	642.94
Common Stock	1,016	1,016	1,008	1,008	1,008	1,008
Additional Paid-In Capital	262.77	244.18	102.99	119.41	119.41	49.85
Retained Earnings	6,439	6,138	5,317	4,481	3,783	3,086
Treasury Stock	-98.86	-98.86	-	-	-	-35.32
Comprehensive Income & Other	0.87	0.87	6.75	13.1	10.95	15.09
Total Common Equity	7,620	7,300	6,434	5,622	4,921	4,123
Minority Interest	-26.87	-26.81	-24.03	-37.79	-16.96	-17.5
Shareholders' Equity	7,593	7,274	6,410	5,584	4,904	4,105
Total Liabilities & Equity	8,869	8,440	7,328	6,481	5,697	4,748
Total Debt	60.22	69.27	111.64	92.77	110.91	38.23
Net Cash (Debt)	3,934	3,720	3,382	2,891	2,555	2,201
Net Cash Growth	11.01%	9.99%	16.98%	13.16%	16.08%	13.31%
Net Cash Per Share	3.90	3.68	3.36	2.86	2.53	2.17
Filing Date Shares Outstanding	1,002	1,016	1,008	1,008	1,008	1,008
Total Common Shares Outstanding	1,002	1,016	1,008	1,008	1,008	1,008
Working Capital	5,317	4,993	4,441	3,856	3,361	2,745
Book Value Per Share	7.60	7.18	6.39	5.58	4.88	4.09
Tangible Book Value	7,392	7,068	6,244	5,510	4,825	4,022
Tangible Book Value Per Share	7.37	6.96	6.20	5.47	4.79	3.99
Buildings	-	613.6	599.08	593.38	569.55	604.46
Machinery	-	1,546	1,341	1,251	1,088	934.72
Construction In Progress	-	309.38	293.76	92.07	17.21	3.7

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.